Swedish Orphan Biovitrum Third Quarter 2024 Earnings: Beats Expectations

Swedish Orphan Biovitrum (STO:SOBI) Third Quarter 2024 Results

Key Financial Results

• Revenue: kr6.89b (up 33% from 3Q 2023).
• Net income: kr1.46b (up by kr1.37b from 3Q 2023).
• Profit margin: 21% (up from 1.8% in 3Q 2023). The increase in margin was driven by higher revenue.
• EPS: kr4.27 (up from kr0.30 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Swedish Orphan Biovitrum Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 95%.

Looking ahead, revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are up 12% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Swedish Orphan Biovitrum that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.